Organon & Co | OGN - Cost Of Sales


Organon & Co reported $745M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Celltrion KRW 402.86B 14.24B Sep/2025
Cspc Pharmaceutical CNY 2.11B 173.58M Dec/2025
Deva Holding AS TRY 991.13M 182.81M Sep/2023
Divis Laboratories Ltd INR 10.63B 1.23B Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Kangmei Pharma CNY 1.11B 84.66M Sep/2025
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Laboratorios Farma EUR 186.09M 11.06M Dec/2023
Medical Developments International AUD 7.09M 4.91M Dec/2025
Merck USD 3.32B 531M Dec/2025
Neuren Pharmaceuticals AUD 7.45M 6.56M Jun/2025
Novartis USD 3.54B 7M Dec/2025
Organigram Holdings CAD 56.93M 20.53M Dec/2025
Organon & Co USD 745M 25M Sep/2025
Pharma Mar EUR 3.77M 1.47M Dec/2025
Qiagen NV USD 217.43M 29.65M Dec/2025
Sartorius EUR 484.6M 46.6M Mar/2026
Sino Biopharmaceutical CNY 3.08B 589.65M Jun/2025
Tilray USD 164.37M 8.41M Sep/2025
Zealand Pharma A/S 410K 5K Jun/2025